{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:28:28Z","timestamp":1791912508971,"version":"4.3.4"},"reference-count":232,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,4,23]],"date-time":"2018-04-23T00:00:00Z","timestamp":1524441600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["GRK 1727, CRU303, EXC 306\/2"],"award-info":[{"award-number":["GRK 1727, CRU303, EXC 306\/2"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.00835","type":"journal-article","created":{"date-parts":[[2018,4,23]],"date-time":"2018-04-23T04:17:41Z","timestamp":1524457061000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":279,"title":["Targeting B Cells and Plasma Cells in Autoimmune Diseases"],"prefix":"10.3389","volume":"9","author":[{"given":"Katharina","family":"Hofmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Katrin","family":"Clauder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf Armin","family":"Manz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,4,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1146\/annurev.immunol.23.021704.115723","article-title":"Maintenance of serum antibody levels","volume":"23","author":"Manz","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/aps.2015.76","article-title":"Prednisone treatment inhibits the differentiation of B lymphocytes into plasma cells in MRL\/MpSlac-lpr mice","volume":"36","author":"Yan","year":"2015","journal-title":"Acta Pharmacol Sin"},{"key":"B3","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1172\/JCI111757","article-title":"Effects of in vitro corticosteroids on B cell activation, proliferation, and differentiation","volume":"75","author":"Cupps","year":"1985","journal-title":"J Clin Invest"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1172\/JCI112922","article-title":"Selective effects of cyclophosphamide therapy on activation, proliferation, and differentiation of human B cells","volume":"79","author":"Zhu","year":"1987","journal-title":"J Clin Invest"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1002\/art.38736","article-title":"Distinct effects of methotrexate and etanercept on the B cell compartment in patients with juvenile idiopathic arthritis","volume":"66","author":"Glaesener","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1016\/j.yexcr.2011.02.005","article-title":"BAFF inhibition: a new class of drugs for the treatment of autoimmunity","volume":"317","author":"Liu","year":"2011","journal-title":"Exp Cell Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.3389\/fimmu.2017.01245","article-title":"Therapeutic antibodies: what have we learnt from targeting CD20 and where are we going?","volume":"8","author":"Marshall","year":"2017","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40261-016-0426-7","article-title":"Pharmacokinetics, pharmacodynamics and preliminary observations for clinical activity and safety of multiple doses of human mouse chimeric anti-CD22 monoclonal antibody (SM03) in Chinese patients with systemic lupus erythematosus","volume":"36","author":"Zhao","year":"2016","journal-title":"Clin Drug Investig"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1136\/annrheumdis-2014-206016","article-title":"The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus","volume":"74","author":"Alexander","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1136\/annrheumdis-2013-203993","article-title":"Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study","volume":"74","author":"Emery","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial","volume":"54","author":"Emery","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B12","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1080\/14737175.2017.1245616","article-title":"Anti-CD20 monoclonal antibodies in multiple sclerosis","volume":"17","author":"Moreno Torres","year":"2017","journal-title":"Expert Rev Neurother"},{"key":"B13","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.coi.2008.03.014","article-title":"Peripheral B cell subsets","volume":"20","author":"Allman","year":"2008","journal-title":"Curr Opin Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/nri2849","article-title":"The importance of natural IgM: scavenger, protector and regulator","volume":"10","author":"Ehrenstein","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3389\/fimmu.2012.00066","article-title":"Protective roles of natural IgM antibodies","volume":"3","author":"Gronwall","year":"2012","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3389\/fimmu.2016.00108","article-title":"Expansion of B-1a cells with germline heavy chain sequence in lupus mice","volume":"7","author":"Holodick","year":"2016","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.clim.2004.08.019","article-title":"B-lymphocytes, innate immunity, and autoimmunity","volume":"114","author":"Viau","year":"2005","journal-title":"Clin Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1600-065X.2000.imr017517.x","article-title":"B-cell commitment, development and selection","volume":"175","author":"Hardy","year":"2000","journal-title":"Immunol Rev"},{"key":"B19","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1034\/j.1600-065X.2000.00609.x","article-title":"Immunobiology of the immature B cell: plasticity in the B-cell antigen receptor-induced response fine tunes negative selection","volume":"176","author":"King","year":"2000","journal-title":"Immunol Rev"},{"key":"B20","first-page":"11","article-title":"Selection of B cell clones and memory B cells","volume":"4","author":"George","year":"1992","journal-title":"Semin Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1126\/science.286.5447.2098","article-title":"Chemokines and cell migration in secondary lymphoid organs","volume":"286","author":"Cyster","year":"1999","journal-title":"Science"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e386","DOI":"10.1212\/NXI.0000000000000386","article-title":"Frequencies of neuronal autoantibodies in healthy controls: estimation of disease specificity","volume":"4","author":"Lang","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B23","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nrrheum.2017.74","article-title":"Antinuclear antibody testing \u2013 misunderstood or misbegotten?","volume":"13","author":"Pisetsky","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1002\/cyto.b.20547","article-title":"Human peripheral blood B-cell compartments: a crossroad in B-cell traffic","volume":"78","author":"Perez-Andres","year":"2010","journal-title":"Cytometry B Clin Cytom"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1084\/jem.189.9.1513","article-title":"Identification of CD22 ligands on bone marrow sinusoidal endothelium implicated in CD22-dependent homing of recirculating B cells","volume":"189","author":"Nitschke","year":"1999","journal-title":"J Exp Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"6027","DOI":"10.4049\/jimmunol.1102639","article-title":"The skin, a novel niche for recirculating B cells","volume":"188","author":"Geherin","year":"2012","journal-title":"J Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.coi.2017.03.007","article-title":"Deconstructing the germinal center, one cell at a time","volume":"45","author":"Dufaud","year":"2017","journal-title":"Curr Opin Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.imlet.2017.06.006","article-title":"The discovery of plasma cells: an historical note","volume":"188","author":"Ribatti","year":"2017","journal-title":"Immunol Lett"},{"key":"B29","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3389\/fendo.2016.00144","article-title":"Excessive cytosolic DNA fragments as a potential trigger of Graves\u2019 disease: an encrypted message sent by animal models","volume":"7","author":"Luo","year":"2016","journal-title":"Front Endocrinol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/j.1600-065X.1998.tb01447.x","article-title":"Somatic hypermutation in normal and transformed human B cells","volume":"162","author":"Klein","year":"1998","journal-title":"Immunol Rev"},{"key":"B31","doi-asserted-by":"publisher","first-page":"E546","DOI":"10.1073\/pnas.1416276112","article-title":"Functional capacities of human IgM memory B cells in early inflammatory responses and secondary germinal center reactions","volume":"112","author":"Seifert","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B32","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.imlet.2016.05.010","article-title":"Control of memory B cell responses by extrinsic and intrinsic mechanisms","volume":"178","author":"Wienands","year":"2016","journal-title":"Immunol Lett"},{"key":"B33","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1146\/annurev.iy.09.040191.001205","article-title":"Memory B and T cells","volume":"9","author":"Vitetta","year":"1991","journal-title":"Annu Rev Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/j.1749-6632.1997.tb52060.x","article-title":"Human peripheral B cell development. sIgM-IgD+CD38+ hypermutated germinal center centroblasts preferentially express Ig lambda light chain and have undergone mu-to-delta switch","volume":"815","author":"Arpin","year":"1997","journal-title":"Ann N Y Acad Sci"},{"key":"B35","doi-asserted-by":"publisher","first-page":"686","DOI":"10.4049\/jimmunol.170.2.686","article-title":"Intrinsic differences in the proliferation of naive and memory human B cells as a mechanism for enhanced secondary immune responses","volume":"170","author":"Tangye","year":"2003","journal-title":"J Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1084\/jem.20130323","article-title":"Naive and memory human B cells have distinct requirements for STAT3 activation to differentiate into antibody-secreting plasma cells","volume":"210","author":"Deenick","year":"2013","journal-title":"J Exp Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1084\/jem.20020881","article-title":"Silencing of B cell receptor signals in human naive B cells","volume":"196","author":"Feldhahn","year":"2002","journal-title":"J Exp Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1073\/pnas.0437996100","article-title":"Transcriptional analysis of the B cell germinal center reaction","volume":"100","author":"Klein","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B39","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1038\/ni.3458","article-title":"Germinal center B cells recognize antigen through a specialized immune synapse architecture","volume":"17","author":"Nowosad","year":"2016","journal-title":"Nat Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1002\/eji.201746952","article-title":"The strength of BCR signaling shapes terminal development of follicular helper T cells in mice","volume":"47","author":"Sacquin","year":"2017","journal-title":"Eur J Immunol"},{"key":"B41","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1182\/blood.V91.1.173","article-title":"Generation of plasma cells from peripheral blood memory B cells: synergistic effect of interleukin-10 and CD27\/CD70 interaction","volume":"91","author":"Agematsu","year":"1998","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1002\/eji.1830201223","article-title":"CD27 expression by a distinct subpopulation of human B lymphocytes","volume":"20","author":"Maurer","year":"1990","journal-title":"Eur J Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"5669","DOI":"10.4049\/jimmunol.167.10.5669","article-title":"Immunological memory: contribution of memory B cells expressing costimulatory molecules in the resting state","volume":"167","author":"Bar-Or","year":"2001","journal-title":"J Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/1074-7613(95)90048-9","article-title":"Memory B cells from human tonsils colonize mucosal epithelium and directly present antigen to T cells by rapid up-regulation of B7-1 and B7-2","volume":"2","author":"Liu","year":"1995","journal-title":"Immunity"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.4049\/jimmunol.169.4.1676","article-title":"Cytokine control of memory B cell homing machinery","volume":"169","author":"Roy","year":"2002","journal-title":"J Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1182\/blood-2004-08-2992","article-title":"Regulation of CXCR3 and CXCR4 expression during terminal differentiation of memory B cells into plasma cells","volume":"105","author":"Muehlinghaus","year":"2005","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","first-page":"966","DOI":"10.3389\/fimmu.2017.00966","article-title":"Chronic exposure to malaria is associated with inhibitory and activation markers on atypical memory B cells and marginal zone-like B cells","volume":"8","author":"Ubillos","year":"2017","journal-title":"Front Immunol"},{"key":"B48","first-page":"241","article-title":"Immunological memory stabilizing autoreactivity","volume":"305","author":"Manz","year":"2006","journal-title":"Curr Top Microbiol Immunol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1093\/rheumatology\/kex067","article-title":"Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples","volume":"56","author":"Reddy","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"B50","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.nmd.2017.06.012","article-title":"Memory B cell resurgence requires repeated rituximab in myasthenia gravis","volume":"27","author":"Muto","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"B51","doi-asserted-by":"publisher","first-page":"e93222","DOI":"10.1172\/jci.insight.93222","article-title":"Robust memory responses against influenza vaccination in pemphigus patients previously treated with rituximab","volume":"2","author":"Cho","year":"2017","journal-title":"JCI Insight"},{"key":"B52","doi-asserted-by":"publisher","first-page":"E5281","DOI":"10.1073\/pnas.1511270112","article-title":"Complexity of the human memory B-cell compartment is determined by the versatility of clonal diversification in germinal centers","volume":"112","author":"Budeus","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1038\/ni.1814","article-title":"Multiple layers of B cell memory with different effector functions","volume":"10","author":"Dogan","year":"2009","journal-title":"Nat Immunol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1182\/blood-2004-07-2507","article-title":"Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response","volume":"105","author":"Odendahl","year":"2005","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1097\/00000478-200608000-00004","article-title":"Mantle cell lymphoma with plasma cell differentiation","volume":"30","author":"Young","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s00393-014-1438-4","article-title":"[Plasma cells]","volume":"74","author":"Hiepe","year":"2015","journal-title":"Z Rheumatol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1084\/jem.20040168","article-title":"Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB\/W mice","volume":"199","author":"Hoyer","year":"2004","journal-title":"J Exp Med"},{"key":"B58","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1084\/jem.194.1.45","article-title":"A coordinated change in chemokine responsiveness guides plasma cell movements","volume":"194","author":"Hargreaves","year":"2001","journal-title":"J Exp Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1084\/jem.20061289","article-title":"Plasma cell S1P1 expression determines secondary lymphoid organ retention versus bone marrow tropism","volume":"203","author":"Kabashima","year":"2006","journal-title":"J Exp Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.coi.2006.03.004","article-title":"Stromal niches, plasma cell differentiation and survival","volume":"18","author":"Moser","year":"2006","journal-title":"Curr Opin Immunol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1172\/JCI119286","article-title":"Differential expression of tissue-specific adhesion molecules on human circulating antibody-forming cells after systemic, enteric, and nasal immunizations. A molecular basis for the compartmentalization of effector B cell responses","volume":"99","author":"Quiding-Jarbrink","year":"1997","journal-title":"J Clin Invest"},{"key":"B62","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1002\/eji.1830250203","article-title":"Human circulating specific antibody-forming cells after systemic and mucosal immunizations: differential homing commitments and cell surface differentiation markers","volume":"25","author":"Quiding-J\u00e4rbrink","year":"1995","journal-title":"Eur J Immunol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/eji.200737557","article-title":"Levels of autoantibodies, unlike antibodies to all extrinsic antigen groups, fall following B cell depletion with Rituximab","volume":"38","author":"Ferraro","year":"2008","journal-title":"Eur J Immunol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1189\/jlb.0603279","article-title":"CD38 low IgG-secreting cells are precursors of various CD38 high-expressing plasma cell populations","volume":"75","author":"Arce","year":"2004","journal-title":"J Leukoc Biol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.4049\/jimmunol.1102786","article-title":"Cutting edge: IL-21 derived from human follicular helper T cells acts as a survival factor for secondary lymphoid organ, but not for bone marrow, plasma cells","volume":"188","author":"Rodriguez-Bayona","year":"2012","journal-title":"J Immunol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/0167-5699(94)90273-9","article-title":"Molecular mechanisms regulating CD19, CD20 and CD22 gene expression","volume":"15","author":"Kehrl","year":"1994","journal-title":"Immunol Today"},{"key":"B67","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/ar3909","article-title":"Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity","volume":"14","author":"Mei","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"B68","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1186\/ar3908","article-title":"B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies","volume":"15","author":"Leandro","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"B69","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s13317-010-0013-5","article-title":"Serum levels of anti-CCP antibodies, anti-MCV antibodies and RF IgA in the follow-up of patients with rheumatoid arthritis treated with rituximab","volume":"1","author":"Fabris","year":"2010","journal-title":"Auto Immun Highlights"},{"key":"B70","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/nm1763","article-title":"The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis","volume":"14","author":"Neubert","year":"2008","journal-title":"Nat Med"},{"key":"B71","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3389\/fimmu.2017.00603","article-title":"Mechanisms of autoantibody-induced pathology","volume":"8","author":"Ludwig","year":"2017","journal-title":"Front Immunol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1196\/annals.1361.044","article-title":"IL-10 and the cytokine network in the pathogenesis of human autoimmune hemolytic anemia","volume":"1051","author":"Toriani-Terenzi","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"B73","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1159\/000468928","article-title":"Thyroid autoimmunity and thyroid cancer: review focused on cytological studies","volume":"6","author":"Boi","year":"2017","journal-title":"Eur Thyroid J"},{"key":"B74","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.berh.2017.09.007","article-title":"Drivers of the immunopathogenesis in systemic lupus erythematosus","volume":"31","author":"Rose","year":"2017","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3389\/fimmu.2017.00521","article-title":"Thyroid autoimmunity: role of anti-thyroid antibodies in thyroid and extra-thyroidal diseases","volume":"8","author":"Frohlich","year":"2017","journal-title":"Front Immunol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nature13868","article-title":"IgG1 protects against renal disease in a mouse model of cryoglobulinaemia","volume":"517","author":"Strait","year":"2015","journal-title":"Nature"},{"key":"B77","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nri2206","article-title":"Fcgamma receptors as regulators of immune responses","volume":"8","author":"Nimmerjahn","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1016\/j.jaci.2012.02.037","article-title":"Tolerance induction with T cell-dependent protein antigens induces regulatory sialylated IgGs","volume":"129","author":"Oefner","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1038\/nm.2862","article-title":"Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcgammaRIIB and dectin-1","volume":"18","author":"Karsten","year":"2012","journal-title":"Nat Med"},{"key":"B80","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1007\/s10875-010-9405-6","article-title":"A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs","volume":"30","author":"Anthony","year":"2010","journal-title":"J Clin Immunol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"3788","DOI":"10.1172\/JCI65938","article-title":"T cell-independent B cell activation induces immunosuppressive sialylated IgG antibodies","volume":"123","author":"Hess","year":"2013","journal-title":"J Clin Invest"},{"key":"B82","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/ni.3579","article-title":"Regulation of autoantibody activity by the IL-23-TH17 axis determines the onset of autoimmune disease","volume":"18","author":"Pfeifle","year":"2017","journal-title":"Nat Immunol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/nrrheum.2017.146","article-title":"Differential antibody glycosylation in autoimmunity: sweet biomarker or modulator of disease activity?","volume":"13","author":"Seeling","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"642","DOI":"10.3389\/fimmu.2015.00642","article-title":"B cells are multifunctional players in multiple sclerosis pathogenesis: insights from therapeutic interventions","volume":"6","author":"Claes","year":"2015","journal-title":"Front Immunol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1016\/j.jaci.2015.10.018","article-title":"IL-10 mediates plasmacytosis-associated immunodeficiency by inhibiting complement-mediated neutrophil migration","volume":"137","author":"Kulkarni","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1038\/ni833","article-title":"B cells regulate autoimmunity by provision of IL-10","volume":"3","author":"Fillatreau","year":"2002","journal-title":"Nat Immunol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"3498","DOI":"10.4049\/jimmunol.176.6.3498","article-title":"Primary T cell expansion and differentiation in vivo requires antigen presentation by B cells","volume":"176","author":"Crawford","year":"2006","journal-title":"J Immunol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1002\/eji.200425732","article-title":"B cells can prime naive CD4+ T cells in vivo in the absence of other professional antigen-presenting cells in a CD154-CD40-dependent manner","volume":"35","author":"Rodriguez-Pinto","year":"2005","journal-title":"Eur J Immunol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1084\/jem.181.3.1081","article-title":"Interleukin 4 production by CD4+ T cells from allergic individuals is modulated by antigen concentration and antigen-presenting cell type","volume":"181","author":"Secrist","year":"1995","journal-title":"J Exp Med"},{"key":"B90","doi-asserted-by":"crossref","first-page":"388","DOI":"10.4049\/jimmunol.140.2.388","article-title":"Studies on the capacity of intact cells and purified Ia from different B cell sources to function in antigen presentation to T cells","volume":"140","author":"Krieger","year":"1988","journal-title":"J Immunol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/ni.2569","article-title":"Trypanosoma cruzi trans-sialidase initiates a program independent of the transcription factors RORgammat and Ahr that leads to IL-17 production by activated B cells","volume":"14","author":"Bermejo","year":"2013","journal-title":"Nat Immunol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/imr.12374","article-title":"Cytokine-producing B cells: a translational view on their roles in human and mouse autoimmune diseases","volume":"269","author":"Lino","year":"2016","journal-title":"Immunol Rev"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1084\/jem.20111675","article-title":"B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells","volume":"209","author":"Barr","year":"2012","journal-title":"J Exp Med"},{"key":"B94","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/nri3857","article-title":"Antibody-independent functions of B cells: a focus on cytokines","volume":"15","author":"Shen","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/ncprheum0950","article-title":"Activated B cells in autoimmune diseases: the case for a regulatory role","volume":"4","author":"Anderton","year":"2008","journal-title":"Nat Clin Pract Rheumatol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.coi.2014.02.009","article-title":"From the regulatory functions of B cells to the identification of cytokine-producing plasma cell subsets","volume":"28","author":"Dang","year":"2014","journal-title":"Curr Opin Immunol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.clim.2017.07.020","article-title":"B cells and their cytokine activities implications in human diseases","volume":"186","author":"Fillatreau","year":"2017","journal-title":"Clin Immunol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/nature12979","article-title":"IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases","volume":"507","author":"Shen","year":"2014","journal-title":"Nature"},{"key":"B99","doi-asserted-by":"publisher","first-page":"16971","DOI":"10.1074\/jbc.M708459200","article-title":"Induction of cytosolic calcium flux by CD20 is dependent upon B cell antigen receptor signaling","volume":"283","author":"Walshe","year":"2008","journal-title":"J Biol Chem"},{"key":"B100","first-page":"669","article-title":"Rituxan: the new kid on the block","volume":"25","author":"Jonas","year":"1998","journal-title":"Oncol Nurs Forum"},{"key":"B101","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/mus.25597","article-title":"Rituximab treatment of myasthenia gravis: a systematic review","volume":"56","author":"Tandan","year":"2017","journal-title":"Muscle Nerve"},{"key":"B102","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.2147\/DDDT.S139248","article-title":"Current perspective on rituximab in rheumatic diseases","volume":"11","author":"Schioppo","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"B103","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa067752","article-title":"A single cycle of rituximab for the treatment of severe pemphigus","volume":"357","author":"Joly","year":"2007","journal-title":"N Engl J Med"},{"key":"B104","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jneuroim.2006.06.029","article-title":"Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients","volume":"180","author":"Cross","year":"2006","journal-title":"J Neuroimmunol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1093\/rheumatology\/keq116","article-title":"Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study (MIRROR)","volume":"49","author":"Rubbert-Roth","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"B106","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/sji.12070","article-title":"Humoral pattern recognition and the complement system","volume":"78","author":"Degn","year":"2013","journal-title":"Scand J Immunol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1517\/14712598.8.6.759","article-title":"Complement and cellular cytotoxicity in antibody therapy of cancer","volume":"8","author":"Wang","year":"2008","journal-title":"Expert Opin Biol Ther"},{"key":"B108","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1074\/jbc.273.1.344","article-title":"Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment","volume":"273","author":"Deans","year":"1998","journal-title":"J Biol Chem"},{"key":"B109","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.1182\/blood-2003-06-2031","article-title":"Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents","volume":"103","author":"Cragg","year":"2004","journal-title":"Blood"},{"key":"B110","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3324\/haematol.2008.001628","article-title":"Anti-CD20 monoclonal antibodies: historical and future perspectives","volume":"95","author":"Lim","year":"2010","journal-title":"Haematologica"},{"key":"B111","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1615\/ForumImmunDisTher.2015014073","article-title":"CD20 and its antibodies: past, present, and future","volume":"5","author":"Oldham","year":"2014","journal-title":"For Immunopathol Dis Therap"},{"key":"B112","first-page":"5480","article-title":"CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts","volume":"63","author":"Chan","year":"2003","journal-title":"Cancer Res"},{"key":"B113","doi-asserted-by":"publisher","first-page":"R57","DOI":"10.1186\/ar3770","article-title":"Induction of long-term B-cell depletion in refractory rheumatoid arthritis patients preferentially affects autoreactive more than protective humoral immunity","volume":"14","author":"Teng","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"B114","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1182\/blood.V99.6.2154","article-title":"The heterogeneity shown by human plasma cells from tonsil, blood, and bone marrow reveals graded stages of increasing maturity, but local profiles of adhesion molecule expression","volume":"99","author":"Medina","year":"2002","journal-title":"Blood"},{"key":"B115","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1002\/art.11181","article-title":"Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis","volume":"48","author":"Cambridge","year":"2003","journal-title":"Arthritis Rheum"},{"key":"B116","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1056\/NEJMoa062930","article-title":"Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin","volume":"355","author":"Ahmed","year":"2006","journal-title":"N Engl J Med"},{"key":"B117","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1159\/000187431","article-title":"Clinical and immunological follow-up of pemphigus patients on adjuvant treatment with immunoadsorption or rituximab","volume":"218","author":"Pf\u00fctze","year":"2009","journal-title":"Dermatology"},{"key":"B118","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016\u2009update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B119","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.3899\/jrheum.110444","article-title":"Safety and effectiveness of rituximab in patients with rheumatoid arthritis following an inadequate response to 1 prior tumor necrosis factor inhibitor: the RESET Trial","volume":"38","author":"Haraoui","year":"2011","journal-title":"J Rheumatol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3899\/jrheum.131279","article-title":"Longterm followup of rituximab therapy in patients with rheumatoid arthritis: results from the Belgian MabThera in Rheumatoid Arthritis registry","volume":"41","author":"De Keyser","year":"2014","journal-title":"J Rheumatol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.jbspin.2014.06.001","article-title":"High anti-CCP antibody titres predict good response to rituximab in patients with active rheumatoid arthritis","volume":"81","author":"Gardette","year":"2014","journal-title":"Joint Bone Spine"},{"key":"B122","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/acr.21865","article-title":"Predictive factors of rituximab response in rheumatoid arthritis: results from a French university hospital","volume":"65","author":"Couderc","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B123","doi-asserted-by":"publisher","first-page":"3681","DOI":"10.1002\/art.30596","article-title":"Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment","volume":"63","author":"Lal","year":"2011","journal-title":"Arthritis Rheum"},{"key":"B124","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1136\/ard.2010.148759","article-title":"Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries","volume":"70","author":"Chatzidionysiou","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"B125","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s13075-016-1190-z","article-title":"Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis","volume":"18","author":"Sellam","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"B126","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/art.38307","article-title":"Rheumatoid factor as a potentiator of anti-citrullinated protein antibody-mediated inflammation in rheumatoid arthritis","volume":"66","author":"Sokolove","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B127","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jaut.2013.12.002","article-title":"The effect of B-cell depletion therapy on serological evidence of B-cell and plasmablast activation in patients with rheumatoid arthritis over multiple cycles of rituximab treatment","volume":"50","author":"Cambridge","year":"2014","journal-title":"J Autoimmun"},{"key":"B128","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.1600-065X.1990.tb00818.x","article-title":"Mechanisms of immune injury in rheumatoid arthritis: evidence for the involvement of T cells and heat-shock protein","volume":"118","author":"Strober","year":"1990","journal-title":"Immunol Rev"},{"key":"B129","doi-asserted-by":"publisher","first-page":"571","DOI":"10.3389\/fimmu.2015.00571","article-title":"The interplay between monocytes\/macrophages and CD4(+) T cell subsets in rheumatoid arthritis","volume":"6","author":"Roberts","year":"2015","journal-title":"Front Immunol"},{"key":"B130","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/BOR.0000000000000012","article-title":"Genome-wide association studies to advance our understanding of critical cell types and pathways in rheumatoid arthritis: recent findings and challenges","volume":"26","author":"Diogo","year":"2014","journal-title":"Curr Opin Rheumatol"},{"key":"B131","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/nrrheum.2009.183","article-title":"Regulatory T cells as therapeutic targets in rheumatoid arthritis","volume":"5","author":"Esensten","year":"2009","journal-title":"Nat Rev Rheumatol"},{"key":"B132","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.autrev.2010.07.006","article-title":"Predictive factors of response to rituximab therapy in rheumatoid arthritis: what do we know today?","volume":"9","author":"Benucci","year":"2010","journal-title":"Autoimmun Rev"},{"key":"B133","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1002\/art.38107","article-title":"Rituximab-induced T cell depletion in patients with rheumatoid arthritis: association with clinical response","volume":"65","author":"Melet","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B134","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.1002\/art.24998","article-title":"Depletion of functionally active CD20+ T cells by rituximab treatment","volume":"60","author":"Wilk","year":"2009","journal-title":"Arthritis Rheum"},{"key":"B135","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.4049\/jimmunol.1001431","article-title":"TLR and B cell receptor signals to B cells differentially program primary and memory Th1 responses to Salmonella enterica","volume":"185","author":"Barr","year":"2010","journal-title":"J Immunol"},{"key":"B136","doi-asserted-by":"publisher","first-page":"4710","DOI":"10.4049\/jimmunol.167.8.4710","article-title":"T cell activation in rheumatoid synovium is B cell dependent","volume":"167","author":"Takemura","year":"2001","journal-title":"J Immunol"},{"key":"B137","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s10875-010-9456-8","article-title":"TLR1\/2, TLR7, and TLR9 signals directly activate human peripheral blood naive and memory B cell subsets to produce cytokines, chemokines, and hematopoietic growth factors","volume":"31","author":"Agrawal","year":"2011","journal-title":"J Clin Immunol"},{"key":"B138","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1126\/science.1215173","article-title":"Innate response activator B cells protect against microbial sepsis","volume":"335","author":"Rauch","year":"2012","journal-title":"Science"},{"key":"B139","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/eji.201747191","article-title":"Anti-interleukin-6 signalling therapy rebalances the disrupted cytokine production of B cells from patients with active rheumatoid arthritis","volume":"48","author":"Fleischer","year":"2017","journal-title":"Eur J Immunol"},{"key":"B140","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/S0140-6736(88)91781-3","article-title":"Galactosylation of IgG associated oligosaccharides: reduction in patients with adult and juvenile onset rheumatoid arthritis and relation to disease activity","volume":"1","author":"Parekh","year":"1988","journal-title":"Lancet"},{"key":"B141","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1002\/art.27533","article-title":"Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritis","volume":"62","author":"Ercan","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B142","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1126\/science.1129594","article-title":"Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation","volume":"313","author":"Kaneko","year":"2006","journal-title":"Science"},{"key":"B143","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/exd.12171","article-title":"The carbohydrate switch between pathogenic and immunosuppressive antigen-specific antibodies","volume":"22","author":"Collin","year":"2013","journal-title":"Exp Dermatol"},{"key":"B144","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/acr.22993","article-title":"Pragmatic treatment of patients with systemic lupus erythematosus with rituximab: long-term effects on serum immunoglobulins","volume":"69","author":"Reddy","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B145","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B146","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1093\/rheumatology\/kei080","article-title":"B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients","volume":"44","author":"Leandro","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"B147","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1136\/ard.2007.083162","article-title":"Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus","volume":"67","author":"Albert","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"B148","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1002\/art.24341","article-title":"A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients","volume":"61","author":"Lu","year":"2009","journal-title":"Arthritis Rheum"},{"key":"B149","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"key":"B150","doi-asserted-by":"publisher","first-page":"1352458517720044","DOI":"10.1177\/1352458517720044","article-title":"Rituximab in multiple sclerosis: frequency and clinical relevance of anti-drug antibodies","author":"Dunn","year":"2017","journal-title":"Mult Scler"},{"key":"B151","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/ana.21867","article-title":"Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial","volume":"66","author":"Hawker","year":"2009","journal-title":"Ann Neurol"},{"key":"B152","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nri2315","article-title":"Not always the bad guys: B cells as regulators of autoimmune pathology","volume":"8","author":"Fillatreau","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"B153","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.immuni.2014.10.016","article-title":"Interleukin-10-producing plasmablasts exert regulatory function in autoimmune inflammation","volume":"41","author":"Matsumoto","year":"2014","journal-title":"Immunity"},{"key":"B154","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s13317-017-0100-y","article-title":"Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment","volume":"8","author":"Du","year":"2017","journal-title":"Auto Immun Highlights"},{"key":"B155","doi-asserted-by":"publisher","first-page":"e87379","DOI":"10.1371\/journal.pone.0087379","article-title":"Safety with ocrelizumab in rheumatoid arthritis: results from the ocrelizumab phase III program","volume":"9","author":"Emery","year":"2014","journal-title":"PLoS One"},{"key":"B156","doi-asserted-by":"publisher","first-page":"571","DOI":"10.4161\/mabs.21338","article-title":"CD19 as an attractive target for antibody-based therapy","volume":"4","author":"Hammer","year":"2012","journal-title":"MAbs"},{"key":"B157","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1001\/jamaoncol.2017.2380","article-title":"Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD for patients with relapsed or refractory philadelphia chromosome-negative acute lymphoblastic leukemia: a phase 2 clinical trial","volume":"4","author":"Jabbour","year":"2018","journal-title":"JAMA Oncol"},{"key":"B158","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/nrrheum.2009.184","article-title":"CD19: a promising B cell target for rheumatoid arthritis","volume":"5","author":"Tedder","year":"2009","journal-title":"Nat Rev Rheumatol"},{"key":"B159","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13063-017-1857-z","article-title":"Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial","volume":"18","author":"Gopaluni","year":"2017","journal-title":"Trials"},{"key":"B160","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.smim.2006.04.006","article-title":"BAFF, APRIL and their receptors: structure, function and signaling","volume":"18","author":"Bossen","year":"2006","journal-title":"Semin Immunol"},{"key":"B161","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/35010115","article-title":"TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease","volume":"404","author":"Gross","year":"2000","journal-title":"Nature"},{"key":"B162","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1136\/annrheumdis-2012-202844","article-title":"Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids","volume":"72","author":"Condon","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B163","first-page":"468","article-title":"Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases","volume":"28","author":"Ramos-Casals","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"B164","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s40265-018-0872-z","article-title":"Belimumab: a review in systemic lupus erythematosus","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"key":"B165","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/art.27189","article-title":"Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study","volume":"62","author":"Jacobi","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B166","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3899\/jrheum.121368","article-title":"Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus","volume":"41","author":"Ginzler","year":"2014","journal-title":"J Rheumatol"},{"key":"B167","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1002\/art.34400","article-title":"Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus","volume":"64","author":"Stohl","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B168","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1136\/annrheumdis-2014-207090","article-title":"Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study","volume":"74","author":"Smolen","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B169","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1186\/s13075-014-0415-2","article-title":"A 52-week, open-label study evaluating the safety and efficacy of tabalumab, an anti-B-cell-activating factor monoclonal antibody, for rheumatoid arthritis","volume":"16","author":"Greenwald","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"B170","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1002\/art.30373","article-title":"Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial","volume":"63","author":"Genovese","year":"2011","journal-title":"Arthritis Rheum"},{"key":"B171","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1002\/art.30372","article-title":"Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial","volume":"63","author":"van Vollenhoven","year":"2011","journal-title":"Arthritis Rheum"},{"key":"B172","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"B173","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"key":"B174","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1136\/annrheumdis-2015-207654","article-title":"Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study","volume":"75","author":"Merrill","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B175","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1136\/annrheumdis-2013-205144","article-title":"A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study","volume":"74","author":"Furie","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B176","doi-asserted-by":"publisher","first-page":"4142","DOI":"10.1002\/art.23047","article-title":"Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial","volume":"56","author":"Dall\u2019Era","year":"2007","journal-title":"Arthritis Rheum"},{"key":"B177","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s10067-013-2245-z","article-title":"ANA (+) ANCA (+) systemic vasculitis associated with the use of minocycline: case-based review","volume":"32","author":"Lenert","year":"2013","journal-title":"Clin Rheumatol"},{"key":"B178","doi-asserted-by":"publisher","first-page":"R33","DOI":"10.1186\/ar3738","article-title":"Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial","volume":"14","author":"Ginzler","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"B179","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1136\/annrheumdis-2013-203991","article-title":"Efficacy and safety of belimumab in primary Sjogren\u2019s syndrome: results of the BELISS open-label phase II study","volume":"74","author":"Mariette","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B180","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S1474-4422(14)70028-6","article-title":"Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial","volume":"13","author":"Kappos","year":"2014","journal-title":"Lancet Neurol"},{"key":"B181","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3899\/jrheum.120886","article-title":"Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging study","volume":"40","author":"Stohl","year":"2013","journal-title":"J Rheumatol"},{"key":"B182","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/40540","article-title":"Lifetime of plasma cells in the bone marrow","volume":"388","author":"Manz","year":"1997","journal-title":"Nature"},{"key":"B183","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/S1074-7613(00)80541-5","article-title":"Humoral immunity due to long-lived plasma cells","volume":"8","author":"Slifka","year":"1998","journal-title":"Immunity"},{"key":"B184","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1681\/ASN.2010010034","article-title":"Myeloperoxidase-specific plasma cell depletion by bortezomib protects from anti-neutrophil cytoplasmic autoantibodies-induced glomerulonephritis","volume":"22","author":"Bontscho","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"B185","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.4049\/jimmunol.1002539","article-title":"Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis","volume":"186","author":"Gomez","year":"2011","journal-title":"J Immunol"},{"key":"B186","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13075-015-0551-3","article-title":"Long-lived plasma cells are early and constantly generated in New Zealand Black\/New Zealand White F1 mice and their therapeutic depletion requires a combined targeting of autoreactive plasma cells and their precursors","volume":"17","author":"Taddeo","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"B187","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.clim.2016.02.009","article-title":"A role for plasma cell targeting agents in immune tolerance induction in autoimmune disease and antibody responses to therapeutic proteins","volume":"165","author":"Rosenberg","year":"2016","journal-title":"Clin Immunol"},{"key":"B188","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1002\/pbc.25172","article-title":"Bortezomib for effective treatment of a child with refractory autoimmune hemolytic anemia post allogeneic hematopoietic stem cell transplant","volume":"61","author":"Mehta","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"B189","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/RHU.0000000000000210","article-title":"Refractory primary Sjogren syndrome successfully treated with bortezomib","volume":"21","author":"Jakez-Ocampo","year":"2015","journal-title":"J Clin Rheumatol"},{"key":"B190","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13075-015-0529-1","article-title":"Proteasome inhibitors as experimental therapeutics of autoimmune diseases","volume":"17","author":"Verbrugge","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"B191","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/j.bbmt.2014.06.032","article-title":"Bortezomib for refractory autoimmunity in pediatrics","volume":"20","author":"Khandelwal","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"B192","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1111\/trf.12614","article-title":"Bortezomib for chronic relapsing thrombotic thrombocytopenic purpura: a case report","volume":"54","author":"Yates","year":"2014","journal-title":"Transfusion"},{"key":"B193","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/ejh.12206","article-title":"Refractory thrombotic thrombocytopenic purpura in a 16-year-old girl: successful treatment with bortezomib","volume":"92","author":"van Balen","year":"2014","journal-title":"Eur J Haematol"},{"key":"B194","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/j.1749-6632.2012.06824.x","article-title":"Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis?","volume":"1274","author":"Gomez","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"B195","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/ajh.21950","article-title":"Successful treatment of IgG and complement-mediated autoimmune hemolytic anemia with bortezomib and low-dose cyclophosphamide","volume":"86","author":"Danchaivijitr","year":"2011","journal-title":"Am J Hematol"},{"key":"B196","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/nrneph.2016.20","article-title":"Plasma cells as an innovative target in autoimmune disease with renal manifestations","volume":"12","author":"Hiepe","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"B197","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/nrrheum.2011.1","article-title":"Long-lived autoreactive plasma cells drive persistent autoimmune inflammation","volume":"7","author":"Hiepe","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"B198","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1093\/intimm\/dxv038","article-title":"The expanding family of regulatory B cells","volume":"27","author":"Mauri","year":"2015","journal-title":"Int Immunol"},{"key":"B199","doi-asserted-by":"publisher","first-page":"e30883","DOI":"10.1371\/journal.pone.0030883","article-title":"Schistosomes induce regulatory features in human and mouse CD1d(hi) B cells: inhibition of allergic inflammation by IL-10 and regulatory T cells","volume":"7","author":"van der Vlugt","year":"2012","journal-title":"PLoS One"},{"key":"B200","doi-asserted-by":"publisher","first-page":"12134","DOI":"10.1038\/ncomms12134","article-title":"Treatment of ongoing autoimmune encephalomyelitis with activated B-cell progenitors maturing into regulatory B cells","volume":"7","author":"Korniotis","year":"2016","journal-title":"Nat Commun"},{"key":"B201","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1146\/annurev-immunol-020711-074934","article-title":"Immune regulatory function of B cells","volume":"30","author":"Mauri","year":"2012","journal-title":"Annu Rev Immunol"},{"key":"B202","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1615\/CritRevImmunol.2015012558","article-title":"Interleukin 35-producing B cells (i35-Breg): a new mediator of regulatory B-cell functions in CNS autoimmune diseases","volume":"35","author":"Egwuagu","year":"2015","journal-title":"Crit Rev Immunol"},{"key":"B203","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.immuni.2015.04.005","article-title":"Regulatory B cells: origin, phenotype, and function","volume":"42","author":"Rosser","year":"2015","journal-title":"Immunity"},{"key":"B204","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.immuni.2009.11.009","article-title":"CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients","volume":"32","author":"Blair","year":"2010","journal-title":"Immunity"},{"key":"B205","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1182\/blood-2014-09-599159","article-title":"CD24(hi)CD27(+) and plasmablast-like regulatory B cells in human chronic graft-versus-host disease","volume":"125","author":"de Masson","year":"2015","journal-title":"Blood"},{"key":"B206","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.4049\/jimmunol.1600218","article-title":"Induction and differentiation of IL-10-producing regulatory B cells from healthy blood donors and rheumatoid arthritis patients","volume":"198","author":"Banko","year":"2017","journal-title":"J Immunol"},{"key":"B207","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1182\/blood-2010-07-294249","article-title":"Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells","volume":"117","author":"Iwata","year":"2011","journal-title":"Blood"},{"key":"B208","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1002\/eji.201343822","article-title":"Autocrine IL-10 promotes human B-cell differentiation into IgM- or IgG-secreting plasmablasts","volume":"44","author":"Heine","year":"2014","journal-title":"Eur J Immunol"},{"key":"B209","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/bjd.13192","article-title":"Impaired function of CD19(+) CD24(hi) CD38(hi) regulatory B cells in patients with pemphigus","volume":"172","author":"Zhu","year":"2015","journal-title":"Br J Dermatol"},{"key":"B210","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1002\/art.38666","article-title":"Regulatory B10 cells are decreased in patients with rheumatoid arthritis and are inversely correlated with disease activity","volume":"66","author":"Daien","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B211","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13075-017-1244-x","article-title":"Th17 and CD24hiCD27+ regulatory B lymphocytes are biomarkers of response to biologics in rheumatoid arthritis","volume":"19","author":"Salomon","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"B212","doi-asserted-by":"publisher","first-page":"173ra23","DOI":"10.1126\/scitranslmed.3005407","article-title":"CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation","volume":"5","author":"Flores-Borja","year":"2013","journal-title":"Sci Transl Med"},{"key":"B213","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/rheumatology\/kev331","article-title":"Decreased levels of regulatory B cells in patients with systemic sclerosis: association with autoantibody production and disease activity","volume":"55","author":"Matsushita","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"B214","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13075-016-1213-9","article-title":"TIM-1 defines a human regulatory B cell population that is altered in frequency and function in systemic sclerosis patients","volume":"19","author":"Aravena","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"B215","doi-asserted-by":"publisher","first-page":"6092","DOI":"10.4049\/jimmunol.178.10.6092","article-title":"Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis","volume":"178","author":"Duddy","year":"2007","journal-title":"J Immunol"},{"key":"B216","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1002\/ana.21939","article-title":"Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?","volume":"67","author":"Bar-Or","year":"2010","journal-title":"Ann Neurol"},{"key":"B217","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jneuroim.2011.08.019","article-title":"Reduction in IL-10 producing B cells (Breg) in multiple sclerosis is accompanied by a reduced naive\/memory Breg ratio during a relapse but not in remission","volume":"239","author":"Knippenberg","year":"2011","journal-title":"J Neuroimmunol"},{"key":"B218","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1093\/intimm\/dxv026","article-title":"Regulatory B cells in human inflammatory and autoimmune diseases: from mouse models to clinical research","volume":"27","author":"Miyagaki","year":"2015","journal-title":"Int Immunol"},{"key":"B219","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/mus.23951","article-title":"Interleukin-10 producing-B cells and their association with responsiveness to rituximab in myasthenia gravis","volume":"49","author":"Sun","year":"2014","journal-title":"Muscle Nerve"},{"key":"B220","doi-asserted-by":"publisher","first-page":"3757","DOI":"10.4049\/jimmunol.1700822","article-title":"Transient BAFF blockade inhibits type 1 diabetes development in nonobese diabetic mice by enriching immunoregulatory B lymphocytes sensitive to deletion by anti-CD20 cotherapy","volume":"199","author":"Wang","year":"2017","journal-title":"J Immunol"},{"key":"B221","doi-asserted-by":"publisher","first-page":"175ra30","DOI":"10.1126\/scitranslmed.3005166","article-title":"Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response","volume":"5","author":"Colliou","year":"2013","journal-title":"Sci Transl Med"},{"key":"B222","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.immuni.2016.02.012","article-title":"A regulatory feedback between plasmacytoid dendritic cells and regulatory B cells is aberrant in systemic lupus erythematosus","volume":"44","author":"Menon","year":"2016","journal-title":"Immunity"},{"key":"B223","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1002\/art.27601","article-title":"The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B224","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1177\/1352458517695892","article-title":"Thymosin-alpha1 expands deficient IL-10-producing regulatory B cell subsets in relapsing-remitting multiple sclerosis patients","volume":"24","author":"Giacomini","year":"2017","journal-title":"Mult Scler"},{"key":"B225","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1038\/nm.3680","article-title":"Regulatory B cells are induced by gut microbiota-driven interleukin-1beta and interleukin-6 production","volume":"20","author":"Rosser","year":"2014","journal-title":"Nat Med"},{"key":"B226","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/nm.3554","article-title":"Interleukin-35 induces regulatory B cells that suppress autoimmune disease","volume":"20","author":"Wang","year":"2014","journal-title":"Nat Med"},{"key":"B227","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1172\/JCI85113","article-title":"Human regulatory B cells in health and disease: therapeutic potential","volume":"127","author":"Mauri","year":"2017","journal-title":"J Clin Invest"},{"key":"B228","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.immuni.2008.03.017","article-title":"A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses","volume":"28","author":"Yanaba","year":"2008","journal-title":"Immunity"},{"key":"B229","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/eji.1830220314","article-title":"Ly-1 B (B-1) cells are the main source of B cell-derived interleukin 10","volume":"22","author":"O\u2019Garra","year":"1992","journal-title":"Eur J Immunol"},{"key":"B230","doi-asserted-by":"publisher","first-page":"7868","DOI":"10.4049\/jimmunol.178.12.7868","article-title":"Novel suppressive function of transitional 2 B cells in experimental arthritis","volume":"178","author":"Evans","year":"2007","journal-title":"J Immunol"},{"key":"B231","doi-asserted-by":"publisher","first-page":"14080","DOI":"10.1073\/pnas.0700326104","article-title":"Apoptotic cells protect mice from autoimmune inflammation by the induction of regulatory B cells","volume":"104","author":"Gray","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B232","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.4049\/jimmunol.1102500","article-title":"Regulatory B10 cells differentiate into antibody-secreting cells after transient IL-10 production in vivo","volume":"188","author":"Maseda","year":"2012","journal-title":"J Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2018.00835\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T07:10:46Z","timestamp":1693638646000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2018.00835\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,23]]},"references-count":232,"alternative-id":["10.3389\/fimmu.2018.00835"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.00835","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,23]]},"article-number":"835"}}